2017
DOI: 10.1001/jamaneurol.2016.4899
|View full text |Cite
|
Sign up to set email alerts
|

Association of Docosahexaenoic Acid Supplementation With Alzheimer Disease Stage in Apolipoprotein E ε4 Carriers

Abstract: High-dose DHA supplementation in APOE4 carriers before the onset of AD dementia can be a promising approach to decrease the incidence of AD. Given the safety profile, availability, and affordability of DHA supplements, refining an ω-3 intervention in APOE4 carriers is warranted.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

4
116
0
1

Year Published

2017
2017
2024
2024

Publication Types

Select...
7
1

Relationship

1
7

Authors

Journals

citations
Cited by 128 publications
(121 citation statements)
references
References 78 publications
4
116
0
1
Order By: Relevance
“…In recent years, polyunsaturated fatty acids like DHA have gained much attention due to promising results in a number of neurodegenerative conditions 20, 21. Moreover, polyunsaturated fatty acids are required for the normal development of the central nervous system and their deficiency can impair cerebral function in mice 22…”
Section: Discussionmentioning
confidence: 99%
“…In recent years, polyunsaturated fatty acids like DHA have gained much attention due to promising results in a number of neurodegenerative conditions 20, 21. Moreover, polyunsaturated fatty acids are required for the normal development of the central nervous system and their deficiency can impair cerebral function in mice 22…”
Section: Discussionmentioning
confidence: 99%
“…58,63 Overall, the results are discordant, due to the heterogeneity of methods used to evaluate the depressive and/or cognitive symptoms, the form, dose and duration of the omega-3 PUFA supplementation, the lack of evaluation of nutritional intake and metabolism of PUFA prior to starting the supplementation, or the lack of evaluation of genotype-associated risk factors. 64 However, despite the discrepancies in the results, it is important to note that several RCTs performed in patients with depressive disorders revealed an additional effect of long chain omega-3 PUFA supplementation to antidepressant treatments. 65 Of note, a recent study identifies that depressive patients presenting a high level of inflammatory markers are more responsive to long chain omega-3 PUFA supplementation.…”
Section: Dietary Omega-3 Pufa Regulate Neuroinflammation and Ecbs: Romentioning
confidence: 99%
“…Concerning cognitive decline, despite poor positive results of PUFA dietary supplementation in Alzheimer's disease (AD) patients, RCTs using DHA supplementation in subjects carrying the apolipoprotein E ε4 (APOE4) allele, a risk factor for AD, reveal an improvement of pre-dementia. 64 Overall, discrepancies in clinical studies strongly support the need for preclinical studies aimed at depicting the mechanisms of omega-3 PUFA on brain dysfunctions, which should help to better target populations at risk of cognitive and mood disorders. In addition, the consideration of omega-3 PUFA levels in food to cover the physiological requirement of these PUFA for an optimal brain function is a challenge for the food industry.…”
Section: Dietary Omega-3 Pufa Regulate Neuroinflammation and Ecbs: Romentioning
confidence: 99%
“…While age is the greatest AD risk factor, genetic variants that may differentially metabolize and deliver PUFA into the brain are now known to contribute to AD pathology. For example, ApoE E4 allele carriers process DHA differently, so study participants with unrelated genotypes may not respond to the same intervention [2]. Serum levels of PUFAs are also controlled by the rate limiting enzyme, delta-6 desaturase.…”
Section: Short Communicationmentioning
confidence: 99%